Assessing brown fat activity in obese patients using semaglutide
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
University of California, Los Angeles · NCT05419726
This study is trying to see if the weight loss medication semaglutide can boost the activity of brown fat in obese people to help them lose weight.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, Los Angeles (other) |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT05419726 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the activity of brown adipose tissue (BAT) in obese individuals who are starting treatment with semaglutide, a GLP-1 agonist. Participants will undergo infrared thermography imaging to measure BAT activity at baseline, and again at 2-4 weeks and 18-20 weeks after starting the medication. The study hypothesizes that semaglutide will enhance BAT activity, leading to increased metabolic rates and weight loss. The findings could provide insights into the mechanisms of weight loss associated with GLP-1 agonists.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are scheduled to start semaglutide for weight loss.
Not a fit: Patients with significant chronic diseases, cancer, or those currently smoking may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of how semaglutide aids weight loss through the activation of brown adipose tissue, potentially leading to improved obesity treatments.
How similar studies have performed: While studies on GLP-1 agonists have shown varying results, this specific approach focusing on BAT activity with semaglutide is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study) * \>18 years of age and willing to participate * Male or post-menopausal females Exclusion Criteria: * History of prior neck surgery and /or neck irradiation * Use of beta blocker agents * Use of any other glucose lowering medication * History of neuropathic disorders (e.g. diabetic neuropathy) * Diabetic patients * Individuals without normal thyroid function * Individuals with cancer * Any significant chronic disease or renal, hepatic or endocrine disease * Current smokers * Inability of patient to provide consent either for medical reasons or psychiatric reasons
Where this trial is running
Los Angeles, California
- UCLA Health — Los Angeles, California, United States (RECRUITING)
Study contacts
- Principal investigator: Preethi Srikanthan, MD — Principal Investigator
- Study coordinator: Preethi Srikanthan, MD
- Email: psrikanthan@mednet.ucla.edu
- Phone: 310-825-7922
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Obesity